MEDIPOLYMER is a medtech company in the field of biomaterials and regenerative medicine
The recent increase in the elderly population and refractory disease patients has raised societal costs.
MEDIPOLYMER was established with the goal of seeking improved treatment and quality of life for patients with senile and refractory disease. With our vision of ‘pursuing a world with improved quality of life’, we develop functional biomaterials to target chronic diseases. Further, we plan to expand our focus to long-term sustained release formulations of therapeutic drugs and regenerative medicine-intrinsic stem cell activation therapeutics.
Using our versatile functional biomaterials, we work together with clinical experts to develop and supply essential products for patients. One of our focus aims to ensure convenient drug administration for chronic disease patients. Long-term drug efficiency for dementia patients and direct application for rheumatism patients are some of our ongoing developments.
We continuously secure new concepts of drug delivery technology that can maintain long-term treatment efficiency and reduce treatment costs for patients. Moreover, we endeavor to ease the burden to patients, their families and medical staff not only in Korea but around the world with our technology.
For universities, research institutes, and companies interested in utilizing regenerative medicine to treat damaged tissues, MEDIPOLYMER is open to collaboration opportunities. We strive to be a company that leads the development and commercialization of differentiated technologies that offer regenerative medicinal treatment and better quality of life to the global population.
Safety of oneself and the community
supports the health of a society
Growth has power and force when we
contribute to the betterment of society
Aimed to facilitate each person
with technology in the journey of life
Common conditions in older age include hearing loss, osteoarthritis, diabetes, depression, and dementia. Several of these conditions are experienced at the same time as people age. Over 80% of adults over 60 years old have at least one chronic condition. These patients have to take drugs on a daily basis which is a hassle.
Patient compliance/adherence indicates the degree to which a patient correctly follows medical prescription or advice. About 75% of patients are noncompliant in one way or another by missing a dose or not taking the drug altogether which affects the therapeutic regimen. In the US, noncompliance costs the economy between $100 billion to $300 billion annually including the costs from avoidable hospitalizations and premature deaths.
September
September
May
December
July
June
April
February
